| Financial Highlights | Financial Review | | Management’s Report | Audit Committee’s Report | | Independent Auditors’ Report | Financial Statements | | Notes to Financial Statements | | Directors, Committees, and Officers | | Corporate and Shareholder Information |

	Notes to Consolidated Financial Statements (Section 7 of 7)
	On This Page: | 20. Subsequent Event | 21. Segment Information and Geographic Data |
	20. Subsequent Event In January 1998, we completed the sale of the Valleylab business — a part of the Medical Technology Group — to United States Surgical Corporation for $425 million. In connection with this transaction, a gain is expected to be recorded in the first quarter of 1998. Valleylab manufactures a line of electrosurgical and ultrasonic systems and disposables. The Valleylab business is not significant to our financial position or results of operations. 21. Segment Information and Geographic Data We operate in three business segments. Each separately managed segment offers different products requiring different R&D, production, marketing and distribution strategies. The three segments are: Health care — a broad line of: (a) pharmaceutical products (including treatments for heart diseases, infectious diseases, central nervous system disorders, diabetes, arthritis/inflammation and allergies) (b) medical technology products (prosthetic bone and joint devices, specialty instruments and implantable devices, products for diagnosing and treating heart diseases, surgical devices and urological implants) Animal health — products for livestock and pets including antibiotic and feed supplements, vaccines and other veterinary items. Consumer health care — over-the-counter health care and personal care products. We sell our products primarily to customers in the wholesaler sector. In 1997, sales to one wholesaler accounted for 10% of total revenues. Sales to our four largest wholesalers in 1997 represented 34% of total revenues. These sales were concentrated in the health care segment. Revenues were in excess of $10 million in each of 44 countries outside the U.S. in 1997. The U.S. was the only country to contribute more than 10% to total revenues. See the Segment Information and Geographic Data tables in the Financial Statements section.

	Advisory Information for Investors
	Copyright © 1997, 1998 Pfizer Inc All rights reserved.